İbrahim Bilen· @drbilennn · X·· 10 小时前评分70
正文 · 原文
Breaking from the #ESMO26 Presidential Symposium! 🚨
The Phase 3 DeLLphi-305 trial results mark a historic shift in first-line maintenance therapy for extensive-stage small cell lung cancer.
22 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：İbrahim Bilen · x.com